Medtronic Fixes MiniMed Swap at Ceiling as Reimbursement Momentum Builds

Medtronic fixes MiniMed split-off exchange ratio at 4.5939 shares, retiring up to 55 million shares as it pivots to higher-margin heart and surgical units.

Medtronic has locked in the terms of its MiniMed separation, setting the final exchange ratio for the diabetes unit's split-off at the top of its indicated range. Shareholders tendering each Medtronic share will receive exactly 4.5939 MiniMed Group shares, a figure that triggers the transaction's predefined upper bound.

Assuming full subscription, the medical device maker intends to retire roughly 49,056,639 of its own shares. Should the offer be oversubscribed, that figure could climb to about 55,032,401 shares through the exchange of remaining MiniMed stock. A regulatory filing confirmed the conditions but stopped short of disclosing final acceptance results. Press reports suggested appetite for the offer had cooled heading into the deadline, which passed as scheduled last Friday.

Investors nonetheless greeted the milestone warmly. Medtronic stock added 1.0% on Friday to close at EUR 79.00.

A Portfolio Built Around Higher-Margin Bets

The retreat from diabetes forms part of a broader push toward segments with richer margins and stronger growth. Cardiac rhythm care sits at the center of that effort, and Medtronic is reshuffling its leadership there. Felicia Kurz steps in as vice president and general manager for cardiac ablation solutions, a unit that has logged a string of regulatory wins. On 30 September, the FDA and European regulators cleared the Affera Prism-2 mapping software, while the PulseSelect ProxBox adapter picked up CE marking in Europe.

Clinical evidence is stacking up elsewhere in the portfolio as well. Fresh results from the Spectrum study of the VenaSeal system point to durable outcomes in treating chronic venous disease. Across a two-year review of 125 patients, venous ulcer healing reached 88.1%, with a median time to healing of 92 days. Medtronic says all major commercial US payers now reimburse the system.

Reimbursement coverage has widened markedly. Payers now cover treatment costs for 96% of patients insured commercially or through Medicare. Secured reimbursement is widely viewed in medtech as the make-or-break condition for commercializing new therapies; without binding coverage from large US insurers, hospitals and specialists often hold back from adopting modern treatment methods. That 96% figure opens the door to higher procedure volumes and sharpens Medtronic's competitive standing in venous care.

Billing Codes and Clearances Pile Up

The VenaSeal progress fits a pattern of reimbursement and approval gains. About a week ago, Medtronic secured Category I billing codes for two additional systems: Altaviva, used for urge incontinence, and Symplicity Spyral, aimed at high blood pressure. Such standardized codes make it far easier for US physicians to bill for outpatient procedures. The news has supported the share price, which has climbed 3.0% since the codes were announced.

Surgical instruments are advancing too. The FDA granted 510(k) clearance for navigated ApexCut EM blades for use in sinus surgery. The tool pairs with the Stealth AXiS ENT navigation system, with first clinical procedures in the US slated for later in 2026.

Altaviva has drawn additional clinical backing. Multi-year analysis from the TITAN-2 trial showed sustained reductions in nighttime urinary episodes. For the follow-on ENDURANCE study, Medtronic named Ariana L. Smith of Penn Medicine as national principal investigator. The project will track 170 patients across as many as 30 US sites, building the long-term clinical case for the therapy system.

With MiniMed now carved out, Medtronic is steering its resources squarely toward its most profitable core therapies.